CVRx, Inc.
CVRX
Positions held
Your positionsCVRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $44.76M | Enterprise value | $39.56M | Trailing P/E | — | Forward P/E | -0.89 |
| PEG | — | Price / book | 2.24 | Beta | 0.77 | Dividend yield | 0.00% |
| Revenue growth | 15.6% | Earnings growth | — | Gross margin | 86.9% | Operating margin | -82.9% |
| Profit margin | -84.9% | ROE | -133.4% | ROA | -28.7% | Debt / equity | 2.98 |
| Current ratio | 8.05 | Free cash flow | -$23.80M | Analyst recommendation | none | Mean target | $4.58 |
| 52w high | $11.30 | 52w low | $1.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $15.7M | $14.8M | $16.0M | $14.7M | $13.6M |
| Op margin | -82.9% | -82.3% | -69.8% | -83.5% | -105.8% |
| Net income | -$14.0M | -$13.1M | -$11.9M | -$12.9M | -$14.7M |
| Gross margin | 87.4% | 87.2% | 86.3% | 86.8% | 84.3% |
| Gross profit | $13.7M | $12.9M | $13.8M | $12.8M | $11.4M |
| Operating income | -$13.0M | -$12.2M | -$11.2M | -$12.3M | -$14.4M |
- Revenue +6% vs prior quarter ($16M vs $15M).
- Gross margin 87.4% (was 87.2% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $56.7M | $51.3M | $39.3M | $22.5M |
| Op margin | -90.5% | -116.0% | -109.7% | -189.3% |
| Net income | -$53.3M | -$60.0M | -$41.2M | -$41.4M |
| Gross margin | 85.3% | 83.8% | 84.1% | 77.8% |
| Gross profit | $48.3M | $43.0M | $33.0M | $17.5M |
| Operating income | -$51.3M | -$59.5M | -$43.1M | -$42.5M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
2026-09-21 · Nyxoah Names Loic Moreau Interim CFO as John Landry Steps Down
2026-09-21 · CVRx Names New Chief Financial Officer
2026-09-21 · CVRx Appoints John Landry as Chief Financial Officer
2026-09-17 · Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?
2026-08-28 · CVRx Secures Devoted Health Coverage for Barostim Therapy
2026-08-25 · CVRx Responds to Letter from Pointillist Family Office
2026-08-24 · CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
2026-08-13 · CVRx (CVRX) Q2 2026 Earnings Call Transcript
2026-08-13 · CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
2026-08-11 · CVRx Announces Sales Leadership Transition
Price (daily)
Full chart · RSI · MACD · patterns